Apollo Therapeutics, a Cambridge, UK and Boston, MA- and and Chicago, IL-based portfolio biopharmaceutical company focused on translating fundamental medical research into medicines, raised USD 33.5M in a second close of its Series C financing.
The round, which brought the total amount to $260M, was led by Patient Square Capital and included participation by multiple new investors including M&G plc and two of the largest US public pension plans, along with existing investors including Rock Springs Capital.
The company intends to use the funds to advance pipeline programs through clinical development and further fund its drug discovery and development activities based on breakthroughs in basic medical research made at its partner institutions, license or acquire additional clinical stage programs that meet strict selection criteria.
Led by CEO Dr. Richard Mason, Apollo Therapeutics is a portfolio biopharmaceutical company focused on translating fundamental medical research into medicines. The portfolio-model is built around a centralized management team of capital allocators and functional leaders with deep expertise in pharmaceutical R&D, manufacturing, commercial strategy, fund-raising, and business development, leveraged over a diverse portfolio of therapeutic programs, each led by a dedicated and seasoned asset leader.
FinSMEs
02/01/2024